Consolidated Tomoka Ld Co Com (CTO) Valuation Declined While Intrepid Capital Management Raised Its Holding; As Regeneron Pharmaceuticals (Call) (REGN) Share Value Declined, Laurion Capital Management LP Increased Position by $9.53 Million

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Laurion Capital Management Lp increased its stake in Regeneron Pharmaceuticals (Call) (REGN) by 99.16% based on its latest 2018Q3 regulatory filing with the SEC. Laurion Capital Management Lp bought 23,600 shares as the company’s stock declined 4.42% with the market. The hedge fund held 47,400 shares of the health care company at the end of 2018Q3, valued at $19.15 million, up from 23,800 at the end of the previous reported quarter. Laurion Capital Management Lp who had been investing in Regeneron Pharmaceuticals (Call) for a number of months, seems to be bullish on the $44.19B market cap company. The stock increased 0.16% or $0.67 during the last trading session, reaching $408.73. About 271,460 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 1.07% since January 11, 2018 and is uptrending. It has outperformed by 1.07% the S&P500. Some Historical REGN News: 23/04/2018 – Regeneron at J.P. Morgan Spring Biotech Conference May 8; 16/05/2018 – Sanofi: Dupixent Significantly Improved Measures of Overall Disease Severity, Skin Clearing, Itching; 10/03/2018 – REGENERON PHARMACEUTICALS AND SANOFI SAY WILL OFFER LOWER NET PRICE FOR PRALUENT CHOLESTEROL DRUG FOR HIGHEST-RISK PATIENTS; 10/03/2018 – REGENERON, SANOFI’S PRALUENT CUTS HEART RISKS BY 15% IN STUDY; 24/04/2018 – Biotech stars Schleifer and Yancopoulos share $52M in 2017 compensation, even though Regeneron’s share price swooned Plus $264M for Yancopoulos in vested value; 02/05/2018 – Regeneron Presenting at Barclays Conference Jun 1; 19/03/2018 – With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell; 21/05/2018 – REGENERON, SANOFI: 2 POSITIVE PHASE 3 TRIALS REPORTED IN NEJM; 16/05/2018 – Regeneron, Sanofi: Cemiplimab Monotherapy Resulted in Overall Response Rate of 29 % and Disease Control Rate of 57 %; 10/03/2018 – Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam

Intrepid Capital Management Inc increased its stake in Consolidated Tomoka Ld Co Com (CTO) by 18.33% based on its latest 2018Q3 regulatory filing with the SEC. Intrepid Capital Management Inc bought 14,484 shares as the company’s stock declined 6.83% with the market. The hedge fund held 93,482 shares of the real estate company at the end of 2018Q3, valued at $5.82 million, up from 78,998 at the end of the previous reported quarter. Intrepid Capital Management Inc who had been investing in Consolidated Tomoka Ld Co Com for a number of months, seems to be bullish on the $322.83M market cap company. The stock decreased 0.43% or $0.25 during the last trading session, reaching $58.52. About 545 shares traded. Consolidated-Tomoka Land Co. (NYSEMKT:CTO) has declined 8.35% since January 11, 2018 and is downtrending. It has underperformed by 8.35% the S&P500. Some Historical CTO News: 26/03/2018 – Consolidated-Tomoka Short-Interest Ratio Rises 34% to 29 Days; 13/04/2018 – ISS Recommends Consolidated-Tomoka Shareholders Vote “FOR” All Seven of the Company’s Director Nominees; 16/04/2018 – Leading Independent Proxy Advisory Firm Glass Lewis Recommends Consolidated-Tomoka Shareholders Vote “FOR” All Seven of the; 25/04/2018 – CTO: PRELIM PROXY VOTE SHOWS ALL 7 DIRECTORS REELECTED; 13/04/2018 – ISS Recommends Consolidated-Tomoka Shareholders Vote “FOR” All Seven of the Company’s Director Nominees; 17/04/2018 – CONSOLIDATED-TOMOKA LAND CO – QTRLY DILUTED NET INCOME PER SHARE $1.96; 15/03/2018 – Consolidated-Tomoka: Two of Wintergreen Nominees Have ‘Significant Conflict’; 17/04/2018 – Consolidated-Tomoka 1Q EPS $1.96; 10/04/2018 – Consolidated-Tomoka Releases Investor Presentation and Mails Letter to Shareholders Highlighting Proven Track Record of; 13/04/2018 – Consolidated-Tomoka: ISS Recommends Shareholders Vote for Company’s Board Nominees

Intrepid Capital Management Inc, which manages about $260.57M US Long portfolio, decreased its stake in Cisco Sys Inc Com (NASDAQ:CSCO) by 33,830 shares to 88,975 shares, valued at $4.33M in 2018Q3, according to the filing. It also reduced its holding in Bank New York Mellon Corp Com (NYSE:BK) by 23,835 shares in the quarter, leaving it with 148,671 shares, and cut its stake in Apple Inc Com (NASDAQ:AAPL).

More notable recent Consolidated-Tomoka Land Co. (NYSEAMERICAN:CTO) news were published by: Globenewswire.com which released: “Consolidated Tomoka Completes Sale of Approximately 4 Acres for $935000 – GlobeNewswire” on December 28, 2018, also Globenewswire.com with their article: “Consolidated Tomoka Completes Sale of Approximately 20 Acres for $2.43 Million – GlobeNewswire” published on December 20, 2018, Globenewswire.com published: “Consolidated Tomoka Appoints George R. Brokaw and R. Blakeslee Gable to Its Board of Directors and Announces Retirement of Two Directors in April 2019 – GlobeNewswire” on October 18, 2018. More interesting news about Consolidated-Tomoka Land Co. (NYSEAMERICAN:CTO) were released by: Stockhouse.com and their article: “Advangelists and Mobiquity Technologies Close Merger, Immediately Launch Audience Analysis Product for Programmatic Marketers – Stockhouse” published on December 11, 2018 as well as Stockhouse.com‘s news article titled: “Hanwha Q CELLS’ product portfolio delivers market-leading anti-LeTID performance in Fraunhofer CSP test – Stockhouse” with publication date: December 06, 2018.

Investors sentiment decreased to 1.14 in Q3 2018. Its down 0.05, from 1.19 in 2018Q2. It is negative, as 39 investors sold REGN shares while 173 reduced holdings. 89 funds opened positions while 153 raised stakes. 70.41 million shares or 0.23% more from 70.25 million shares in 2018Q2 were reported. California Pub Employees Retirement System holds 165,141 shares. 966 were reported by Dupont Management. Moreover, Regions Corp has 0.01% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 1,649 shares. Ibm Retirement Fund accumulated 1,527 shares. Stephens Inc Ar accumulated 9,027 shares. Victory Capital Management Inc has 0.01% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Weiss Asset Mgmt Ltd Partnership has 571 shares for 0.02% of their portfolio. Aviva Public Limited Com owns 38,398 shares. Tarbox Family Office holds 0% or 14 shares in its portfolio. Cubist Systematic Strategies Limited Liability Co holds 10,700 shares. Yorktown Mngmt Research Com invested 0.08% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Korea Inv Corporation invested 0.04% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Kistler reported 0.01% stake. Manufacturers Life Insur The reported 80,118 shares stake. Meiji Yasuda Life holds 0.16% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 3,143 shares.

Among 34 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 20 Hold. Therefore 38% are positive. Regeneron Pharmaceuticals Inc. had 139 analyst reports since July 28, 2015 according to SRatingsIntel. As per Monday, August 14, the company rating was maintained by J.P. Morgan. The rating was initiated by Raymond James on Tuesday, September 1 with “Outperform”. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Buy” rating given on Tuesday, April 17 by Credit Suisse. The stock has “Buy” rating by Piper Jaffray on Thursday, January 18. The rating was maintained by Morgan Stanley on Friday, February 9 with “Equal-Weight”. The firm has “Neutral” rating by Chardan Capital Markets given on Monday, August 31. The company was maintained on Thursday, September 7 by Robert W. Baird. On Friday, August 3 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. On Friday, December 1 the stock rating was downgraded by Citigroup to “Neutral”. The rating was maintained by BTIG Research on Tuesday, November 28 with “Buy”.

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Nasdaq.com which released: “Why Regeneron (REGN) Might Surprise This Earnings Season – Nasdaq” on November 05, 2018, also Nasdaq.com with their article: “Regeneron Pharmaceuticals is Now Oversold (REGN) – Nasdaq” published on October 25, 2018, Nasdaq.com published: “Bullish Two Hundred Day Moving Average Cross – REGN – Nasdaq” on July 05, 2018. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Investorplace.com and their article: “Market Leadership’s Odd Couple: Wingstop and Regeneron – Investorplace.com” published on January 09, 2019 as well as Seekingalpha.com‘s news article titled: “Regeneron Reports Q3: Updating Its Growth Prospects – Seeking Alpha” with publication date: November 06, 2018.

Laurion Capital Management Lp, which manages about $4.98 billion and $10.31B US Long portfolio, decreased its stake in Nuveen Arizona Qlty Mun Inc (NAZ) by 63,784 shares to 257,867 shares, valued at $3.01M in 2018Q3, according to the filing. It also reduced its holding in Anadarko Pete Corp (Put) (NYSE:APC) by 17,500 shares in the quarter, leaving it with 115,000 shares, and cut its stake in Goldman Sachs Group Inc (NYSE:GS).

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart